Libimax supplement a bit too potent
This article was originally published in The Tan Sheet
Executive Summary
Nature & Health Co. announces a recall of its male enhancement formula after FDA analysis found samples of Libimax contained tadalafil, the active ingredient in Eli Lilly's Rx erectile dysfunction drug Cialis. FDA warns that tadalafil, in conjunction with nitrates found in prescription cholesterol drugs, can cause a dangerous drop in blood pressure. Brea, Calif.-based Nature & Health said April 27 the recalled product was sold in retail stores in California, Georgia, Illinois, Ohio and Texas. FDA has emphasized it will seize adulterated supplement products when firms fail to comply with recall requests (1"The Tan Sheet" July 28, 2008, p. 15)
You may also be interested in...
ED drugs in "supplements" prompt recalls
Los Angeles-based Haloteco July 13 recalls Libipower Plus, a product marketed as a dietary supplement that tested positive for tadalafil in an FDA lab analysis. Brea, Calif.-based Opteron 1 Inc., doing business as Nature & Health Co., July 15 recalls products labeled as supplements including LibieXtreme, Y-4ever and Herbal Disiac in retail locations in California, Georgia, Illinois, Ohio and Texas after FDA found tadalafil and analogs of other pharmaceutical ingredients used in Rx erectile dysfunction drugs such as Cialis in the products. Nature & Health Co. also recently recalled its Libimax product (1"The Tan Sheet" May 4, 2009, In Brief)
FDA Maintains Pressure Against Adulterated ED Supplements
FDA says its seizure of $74,000 in mislabeled erectile dysfunction supplements from SEI Pharmaceuticals July 24 demonstrates the steps the agency will take when a company fails to heed a warning about an allegedly adulterated product
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”